14 brokers rate Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) as Moderate Buy with an avg target price of $87.85.

14 brokers covering Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) have given it an average "Moderate Buy" rating, with a consensus target price of $87.85. Recent target price increases include Wedbush's $48.00, Cantor Fitzgerald's $115.00, and Robert W. Baird's $72.00. Brokers who have issued a report on the stock in the last year have an average 12-month target price of $90.67.

June 03, 2024
3 Articles